JCR Pharmaceuticals Announces Licensing Agreement with Menagen to Commercialize Agalsidase Beta BS I.V. Infusion [JCR] Across Nine MENAT Markets [Yahoo! Finance]
SUMITOMO CHEM UNSP/ADR (SOMMY)
NASDAQ:AMEX Investor Relations:
sumitomo-chem.co.jp/english/ir
Company Research
Source: JCR
biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced an exclusive licensing agreement with Menagen Pharmaceutical Industries LLC (headquartered in Oman, CEO: Saif Al Hasani, "Menagen") to seek local marketing authorizations and to commercialize Agalsidase Beta BS I.V. Infusion [JCR] (the "product") upon approval across nine MENAT markets. The product is a recombinant enzyme replacement therapy (ERT) for Fabry disease currently marketed in Japan. Under the agreement, Menagen will file local applications in the licensed territories across the MENAT markets, leveraging the product's Japanese approval. The licensed territories include: the Kingdom of Saudi Arabia, United Arab Emirates, the Sultanate of Oman, the State of Kuwait, the State of Qatar, the Kingdom of Bahrain, the Republic of Türkiye, the Republic of Iraq, and the Arab Republic of Egypt. Following local approvals, JCR will supply the product, and Menagen will lead commerc
Show less
Read more
Impact Snapshot
Event Time:
SOMMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SOMMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SOMMY alerts
High impacting SUMITOMO CHEM UNSP/ADR news events
Weekly update
A roundup of the hottest topics
SOMMY
News
- Valent BioSciences and Seipasa Form Strategic Partnership to Bring Novel Biostimulant Products to the U.S. Market [Yahoo! Finance]Yahoo! Finance
- Valent BioSciences and Seipasa Form Strategic Partnership to Bring Novel Biostimulant Products to the U.S. MarketBusiness Wire
- Poxel Reports Revenue for the Third Quarter 2025 [Yahoo! Finance]Yahoo! Finance
- Sumitomo Chemical Company reports Q2 results [Seeking Alpha]Seeking Alpha
- Taoka Chemical (TSE:4113) Net Margin Surge Challenges Dividend Sustainability Concerns [Yahoo! Finance]Yahoo! Finance